Please use this identifier to cite or link to this item:
Title: Sofosbuvir and ribavirin in HCV genotypes 2 and 3
Author: Zeuzem, Stefan
Dusheiko, Geoffrey
Salupere, Riina
Mangia, Alessandra
Flisiak, Robert
Hyland, Robert H.
Illeperuma, Ari
Svarovskaia, Evguenia
Brainard, Diana M.
Symonds, William T.
Subramanian, G.Mani
McHutchison, John G.
Weiland, Ola
Reesink, Hendrik W
Ferenci, Peter
Hézode, Christophe
Esteban, Rafael
Forns, Xavier
VALENCE Investigators.
Keywords: Hepatitis C
Medicaments antivírics
Assaigs clínics
Hepatitis C
Antiviral agents
Clinical trials
Issue Date: 22-May-2014
Publisher: Massachusetts Medical Society
Abstract: BACKGROUND: In clinical trials, treatment with a combination of the nucleotide polymerase inhibitor sofosbuvir and the antiviral drug ribavirin was associated with high response rates among patients with hepatitis C virus (HCV) genotype 2 infection, with lower response rates among patients with HCV genotype 3 infection. METHODS: We conducted a study involving patients with HCV genotype 2 or 3 infection, some of whom had undergone previous treatment with an interferon-based regimen. We randomly assigned 91 patients with HCV genotype 2 infection and 328 with HCV genotype 3 infection, in a 4:1 ratio, to receive sofosbuvir-ribavirin or placebo for 12 weeks. On the basis of emerging data from phase 3 trials indicating that patients with HCV genotype 3 infection had higher response rates when they were treated for 16 weeks, as compared with 12 weeks, the study was unblinded, treatment for all patients with genotype 3 infection was extended to 24 weeks, the placebo group was terminated, and the goals of the study were redefined to be descriptive and not include hypothesis testing. The primary end point was a sustained virologic response at 12 weeks after the end of therapy. RESULTS: Of the 419 patients who were enrolled and treated, 21% had cirrhosis and 58% had received previous interferon-based treatment. The criterion for a sustained virologic response was met in 68 of 73 patients (93%; 95% confidence interval [CI], 85 to 98) with HCV genotype 2 infection who were treated for 12 weeks and in 213 of 250 patients (85%; 95% CI, 80 to 89) with HCV genotype 3 infection who were treated for 24 weeks. Among patients with HCV genotype 3 infection, response rates were 91% and 68% among those without and those with cirrhosis, respectively. The most common adverse events were headache, fatigue, and pruritus. CONCLUSIONS: Therapy with sofosbuvir-ribavirin for 12 weeks in patients with HCV genotype 2 infection and for 24 weeks in patients with HCV genotype 3 infection resulted in high rates of sustained virologic response. (Funded by Gilead Sciences; VALENCE number, NCT01682720.).
Note: Reproducció del document publicat a:
It is part of: New England Journal of Medicine, 2014, vol. 370, num. 21, p. 1993-2001
Related resource:
ISSN: 0028-4793
Appears in Collections:Articles publicats en revistes (Medicina)

Files in This Item:
File Description SizeFormat 
661904.pdf445.04 kBAdobe PDFView/Open

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.